‘On May 1 finishes the phase of administering the third dose to the 48,000 volunteers of the 3rd phase clinical trial of Abdala, in the municipalities of Santiago de Cuba, Guantanamo and Bayamo,’ the Center for Genetic Engineering and Biotechnology (CIGB) specified on Friday on Twitter.
Recently, Dr. Verena Muzio, director of Clinical Research of that institution, informed that they would celebrate the International Workers’ Day in the health areas by applying those last doses to all the volunteers included in the study.
The 3rd phase clinical research stage with this candidate against Covid-19 began on March 22 in those eastern provinces with the application of the first dose to 48,290 subjects for six weeks.
Then, the second dose was administered, which stage ended on April 17, with 47,620 volunteers and satisfactory results; while on April 19, the last two weeks of the application of the third dose began.
Dr. Mucio said that once the vaccination stage of the volunteers is completed, the follow-up of those people will begin in order to assess the appearance of Covid-19 cases with symptomatic infection.